TODOS MED LTD ORD - TOMDF STOCK NEWS

Todos Medical (OTCQB: TOMDF) announced the launch of Tollovid Daily™, a subscription-based immune support supplement featuring a 3CL protease inhibitor. This new product, designed for convenient monthly auto-shipping, aims to enhance consumer accessibility to immune support solutions. CEO Gerald Commission emphasized the affordability and mass market appeal of Tollovid Daily, highlighting the integration of cryptocurrency payment options. The company is also striving to expand distribution channels and will provide further updates on its market presence.

Todos Medical, Ltd. (OTCQB: TOMDF) announced a notice of allowance for a trademark for its oral antiviral drug candidate, Tollovir™, from the USPTO. This follows the completion of a Phase 1/2 clinical study and the enrollment of a Phase 2 trial in Israel. The company aims to engage the FDA for the Emergency Use Authorization pathway for Tollovir. Todos is also focused on advancing clinical studies and ensuring a distinct regulatory branding from its dietary supplement, Tollovid®. Ongoing research includes diagnostic solutions for COVID-19 and cancer detection.

Todos Medical (OTCQB: TOMDF) announced the acceptance of cryptocurrency payments for its wellness products, Tollovid® and Tollovid Daily™, via its website. Customers can now use Bitcoin, Ethereum, Dogecoin, Bitcoin Cash, and Litecoin. CEO Gerald E. Commissiong emphasized the importance of these products for immune support, particularly during health challenges. Both products have FDA Certificates of Free Sale and claim to support healthy immune function. Todos Medical is also focused on developing cancer diagnostics and COVID-19 solutions.

Todos Medical, Ltd. (OTCQB: TOMDF) announced a 90-day moratorium on the conversion and sale of convertible notes, establishing a temporary lockup agreement. The company has retained Univest Securities for a proposed underwritten public offering aimed at uplisting to a national stock exchange. The CEO highlighted increased investor interest due to advancements in COVID testing at Provista Diagnostics and ongoing clinical trials for Tollovir, an oral antiviral. Results from a Phase 1/2 study of Tollovir are expected later this quarter, alongside updates on its ongoing clinical trials.

Todos Medical Ltd. (TOMDF) announced that President & CEO Gerald Commissiong will present at the H.C. Wainwright Annual Global Investment Conference from September 13-15, 2021. The presentation, due to a late invitation, will be recorded on September 13, 2021, and made available afterward. Investors can register to listen via a provided link. Todos Medical, based in Israel with a U.S. lab, focuses on cancer diagnostics and COVID-19 testing. The company has developed proprietary testing technologies and recently entered a joint venture to address COVID-19 diagnostics.

Todos Medical announced its lab, Provista Diagnostics, has validated respiratory panel tests for Influenza A & B, RSV, and hMPV, set for launch in September 2021. This comes as schools reopen amid concerns of increased respiratory illnesses. CEO Gerald Commissiong will discuss these developments on Yahoo! Finance Live today. The company's COVID PCR testing has gained traction, complementing its new respiratory panel, which targets a substantial market opportunity within the $80 billion global COVID testing sector. The expected CMS reimbursement rate is $142.

Todos Medical, Ltd. (OTCQB: TOMDF) has validated the Kogene Biotech PCR Variant Test Kit, enabling the launch of variant testing at its Provista Diagnostics lab by September 2021. This PCR test identifies key mutations, particularly in the Delta variant, and provides results in under an hour. The company anticipates strong demand for variant testing as it addresses the surge in COVID-19 cases, especially breakthrough infections. With the potential for over 5,000 variant tests daily and a solid reimbursement structure, Todos aims to capitalize on a growing market opportunity.

Todos Medical Ltd. (OTCQB: TOMDF) has announced a reference lab agreement with Meadowlands Diagnostics to provide cPass neutralizing antibody blood testing for COVID-19 immunity monitoring. This partnership allows Meadowlands to offer cPass testing to their clients and includes contracts with two New Jersey school systems. The cPass test, which has received FDA Emergency Use Authorization, aims to help healthcare professionals assess COVID-19 immunity. Todos anticipates significant revenue growth as they enhance their testing capabilities and meet rising demand.

Todos Medical, Ltd. (OTCQB: TOMDF) announced that its lab, Provista Diagnostics, will launch the cPass Neutralizing Antibody Blood Test in September 2021 after successfully completing validation studies. This FDA-authorized test aims to assist healthcare providers in monitoring COVID-19 immunity levels, especially in the context of rising breakthrough infections. The company sees significant growth potential in immune monitoring, noting that over 200 million people have received at least one vaccine dose in the U.S. The test could play a crucial role in guiding booster shot administration.